Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 13,538	$ 10,347	$ 27,580	$ 18,317
Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue	6,058	4,401	9,655	6,189
EMEA [Member]
Disaggregation of Revenue [Line Items]
Revenue	3,808	1,959	8,800	5,166
APAC [Member]
Disaggregation of Revenue [Line Items]
Revenue	3,672	3,987	9,125	6,962
Product Sales [Member]
Disaggregation of Revenue [Line Items]
Revenue	3,723	6,600	9,886	12,186
Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue	9,815	3,747	17,694	6,131
Performance Enzymes [Member]
Disaggregation of Revenue [Line Items]
Revenue	11,165	10,347	21,894	18,317
Performance Enzymes [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue	6,058	4,401	9,655	6,189
Performance Enzymes [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Revenue	1,435	1,959	3,114	5,166
Performance Enzymes [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Revenue	3,672	3,987	9,125	6,962
Performance Enzymes [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Revenue	3,723	6,600	9,886	12,186
Performance Enzymes [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue	7,442	3,747	12,008	6,131
Novel Biotherapeutics [Member]
Disaggregation of Revenue [Line Items]
Revenue	2,373	0	5,686	0
Novel Biotherapeutics [Member] | Americas [Member]
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Novel Biotherapeutics [Member] | EMEA [Member]
Disaggregation of Revenue [Line Items]
Revenue	2,373	0	5,686	0
Novel Biotherapeutics [Member] | APAC [Member]
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Novel Biotherapeutics [Member] | Product Sales [Member]
Disaggregation of Revenue [Line Items]
Revenue	0	0	0	0
Novel Biotherapeutics [Member] | Research and Development Revenue [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 2,373	$ 0	$ 5,686	$ 0